Evidence map›Paper›PMID 42321438›Full record

ArticleEuropean journal of clinical pharmacology2026

Correspondence: Strengthening evidence traceability in written drug promotion to support rational prescribing.

M Vijayasimha, M Srikanth

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

M VijayasimhaUniversity Institute of Allied Health Science, Chandigarh University, Mohali, 140413, Punjab, India. vijaya.e19133@cumail.in.ORCID http://orcid.org/0000-0003-2038-7006
M SrikanthPandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Medical Rd, Rohtak, Haryana, 124001, India.ORCID http://orcid.org/0009-0005-8488-6041

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Written promotional materials from pharmaceutical companies continue to influence prescribing behaviour despite evolving regulatory oversight. Recent evidence from the European Journal of Clinical Pharmacology highlights persistent structural limitations in how promotional claims are framed and governed. This correspondence critically examines these findings within the context of contemporary clinical pharmacology, global prescribing pressures, and emerging digital promotion ecosystems. We identify a governance gap between content compliance and evidentiary accountability, and propose an Evidence-Linked Promotion Dossier framework to improve transparency, traceability, and currency of promotional claims. Strengthening evidence linkage in promotion has the potential to support rational prescribing, reduce low-value drug use, and enhance global medicines governance.

Indexed as

Drug IndustryDrug PrescriptionsPractice Patterns, Physicians'HumansClinical pharmacologyDrug promotionEvidence traceabilityGlobal health policyPharmaceutical regulationRational prescribing

Identifiers

PMID42321438

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.